Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2002;2002(4):CD001435.
doi: 10.1002/14651858.CD001435.

Interventions for toxic epidermal necrolysis

S Majumdar  1 , M Mockenhaupt, J- Roujeau, A Townshend
Affiliations

Interventions for toxic epidermal necrolysis

S Majumdar et al. Cochrane Database Syst Rev. 2002.

Abstract

Background: Toxic epidermal necrolysis is a rare condition where a drug reaction induces skin loss, similar to that seen in extensive burns. It is associated with high morbidity and mortality and there is no clear agreement on effective treatment.

Objectives: To assess the effects of all interventions for the treatment of toxic epidermal necrolysis.

Search strategy: We searched the Cochrane Skin Group Specialised Register (March 2001), the Cochrane Controlled Trials Register (March 2001), MEDLINE (1966 to December 2001), EMBASE (1980 to December 2001), DARE (4th Quarter 2001) and CINAHL (1982 to October 2001).

Selection criteria: Randomised controlled trials of therapeutic and supportive interventions that included participants clinically diagnosed with toxic epidermal necrolysis were included.

Data collection and analysis: Two independent reviewers carried out study selection and assessment of methodological quality.

Main results: Only one randomised controlled trial of treatment was identified. This trial compared the effectiveness of thalidomide with placebo and included 22 patients, 12 in the treatment group and 10 in the placebo group. Patients on the treatment arm received thalidomide 200 mg twice daily for 5 days. The main end point was the measurement of the progression of skin detachment after 7 days. Other end points were the overall mortality and severity of the disease evaluated with the simplified acute physiology score. The study was terminated as the mortality on the treatment arm was 83% compared to 30% on the control arm (relative risk 2.78, 95% confidence interval 1.04 to 7.40). No randomised controlled trials of the most commonly used current treatments i.e. systemic steroids, cyclosporin A and intravenous immunoglobulins were found.

Reviewer's conclusions: Treatment with thalidomide was not shown to be effective and was associated with significantly higher mortality than placebo. There is no reliable evidence on which to base treatment for toxic epidermal necrolysis, a disease commonly associated with mortality rates of around 30%. More research is required to understand the mechanisms of toxic epidermal necrolysis. International multi-centre studies are needed in the form of randomised controlled trials, to evaluate treatments for toxic epidermal necrolysis, especially those using high doses of steroid and intravenous immunoglobulins.

PubMed Disclaimer

Conflict of interest statement

None

Figures

1.1
1.1. Analysis
Comparison 1 Thalidomide versus placebo, Outcome 1 Mortality.
See this image and copyright information in PMC

References

References to studies included in this review

Wolkenstein 1998 {published and unpublished data}
    1. Wolkenstein P, Latarjet J, Roujeau JC, Duguet C, Boudeau S, Vaillant L, et al. Randomized comparison of thalidomide versus placebo in toxic epidermal necrolysis. Lancet 1998;352(9140):1586‐9. - PubMed

Additional references

Assier 1995
    1. Assier H. Bastuji‐Garin S, Revuz J, Roujeau JC. Erythema multiforme with mucous membrane involvement and Stevens‐Johnson syndrome are clinically different disorders with distinct causes. Archives of Dermatology 1995;131:540. - PubMed
Bachot 2001
    1. Bachot N, Revuz J, Roujeau JC. Are intravenous immunoglobulins the treatment of Stevens‐Johnson syndrome or toxic epidermal necrolysis?. Allergologie 2001;24:214.
Bastuji‐Garin 1993
    1. Bastuji‐Garin S, Rzany B, Stern RS, Shear NH, Naldi L, Roujeau JC. Classification of cases of toxic epidermal necrolysis, Stevens‐Johnson syndrome, and erythema multiforme. Archives of Dermatology 1993;129(1):92‐6. - PubMed
Bunger 1968
    1. Bunger P, Delventhal G. Azathioprinbehandlung bei einem schweren Krankheitsfall von "Lyell Syndrom". Zeitschrift für Haut und Geschlechtskrankheiten 1968;43:853‐60. - PubMed
Clarke 2000
    1. Clarke M, Oxman AD. Optimal search strategy for RCTs. Cochrane Reviewer's Handbook 4.1 [updated June 2000]. Oxford: The Cochrane Collaboration, 2000:appendix 5c.
DerSimonian 1986
    1. DerSimonian R, Laird N. Meta analysis in clinical trials. Controlled Clinical Trials 1986;7:177‐88. - PubMed
Dolan 1989
    1. Dolan PA, Flowers FP, Sheretz EF. Toxic epidermal necrolysis. Journal of Emergency Medicine 1989;7(1):65‐9. - PubMed
Fine 1985
    1. Fine J. Management of acquired bullous skin diseases. New England Journal of Medicine 1995;133:1475‐84. - PubMed
Halebian 1986
    1. Halebian PH, Corder VJ, Madden MR, Finklestein JL, Shires GT. Improved burn centre survival of patients with toxic epidermal necrolysis managed without corticosteroids. Annals of Surgery 1986;204:503‐12. - PMC - PubMed
Hedges 1985
    1. Hedges LV, Olkin I. Statistical methods for meta‐analysis. New York: Academic Press, 1985.
Heimbach 1987
    1. Heimbach DM, Engrav LH, Marvin JA, Harnar TA, Grube BJ. Toxic epidermal necrolysis: a step forward in treatment. Journal of the American Medical Association 1987;257:2171‐5. - PubMed
Heng 1991
    1. Heng MYC, Allen SG. Efficacy of cyclophosphamide in toxic epidermal necrolysis: clinical and pathophysiological aspects. Journal of the American Academy of Dermatology 1991;25:778‐86. - PubMed
Kelly 1995
    1. Kelly JP, Auquier A, Rzany B, Naldi L, Bastuji‐Garin S, et al. An international collaborative case control study of severe cutaneous adverse reactions (SCAR). Journal of Clinical Epidemiology 1995;48(9):1099‐8. - PubMed
Lyell 1956
    1. Lyell A. Toxic epidermal necrolysis: an eruption resembling scalding of the skin. British Journal of Dermatology 1956;68:355‐61. - PubMed
Mockenhaupt 1996
    1. Mockenhaupt M, Schopf E. Epidemiology of drug induced severe skin reactions. Seminar in Cutaneous Medicine & Surgery 1996;15(4):236‐43. - PubMed
Mockenhaupt 1999
    1. Mockenhaupt M, Schröder W, Schlingmann J, Schneck B, Hering O, Schöpf E. Clinical re‐evaluation of erythema exsudativum multiforme majus and Stevens‐Johnson syndrome resulting in a different etiology. The Journal of Investigative Dermatology 1999;112:661.
Pruitt 1987
    1. Pruitt BA. Burn treatment for the unburned. Journal of the American Medical Association 1987;257:2207‐8. - PubMed
Renfro 1989
    1. Renfro L, Grant‐Kels JM, Daman LA. Drug induced toxic epidermal necrolysis treated with cyclosporin. International Journal of Dermatology 1989;28:441‐4. - PubMed
Revuz 1987
    1. Revuz J, Penso D, Roujeau JC, Guillaume JC, Payne CR, Wechsler J, et al. Toxic epidermal necrolysis: clinical finding and prognosis factors in 87 patients. Archives of Dermatology 1987;123:1160‐65. - PubMed
Revuz 1996
    1. Revuz J, Roujeau JC. Advances in toxic epidermal necrolysis. Seminar in Cutaneous Medicine & Surgery 1996;15(4):258‐66. - PubMed
Roujeau 1995
    1. Roujeau JC, Kelly JP, Naldi L, Rzany B, Stern RS, Anderson T, et al. Medication use and the risk of Stevens‐Johnson syndrome or toxic epidermal necrolysis. New England Journal of Medicine 1990;333:1600‐7. - PubMed
Sakellariou 1991
    1. Sakellariou G, Koukoudis P, Karpouzas J, Alexopoulos E, Papadopoulou D, Chrisomalis F, et al. Plasma exchange (PE) treatment in drug‐induced toxic epidermal necrolysis (TEN). International Journal of Artificial Organs 1991;14(10):634‐8. - PubMed
Schulz 1995
    1. Schulz KF, Chalmers I, Haynes RJ, Altman DG. Empirical evidence of bias: dimensions of methodological quality associated with estimates of treatment effects in controlled trials. Journal of the American Medical Association 1995;273:408‐12. - PubMed
Stables 1993
    1. Stables GI, Lever RS. Toxic epidermal necrolysis and systemic corticosteroids. British Journal of Dermatology 1993;128:357‐60. - PubMed
Viard 1998
    1. Viard I, Wehrli P, Bullani R, Schneider P, Holler N, Salomon D, et al. Inhibition of toxic epidermal necrolysis by blockade of CD95 with human intravenous immunoglobulin. Science 1998;282:490‐3. - PubMed
Villada 1990
    1. Villada G, Roujeau JC, Cordonnier C, Bagot M, Keuntz M, Wechsler J, et al. Toxic epidermal necrolysis after bone marrow transplantation: study of nine cases. Journal of the American Academy of Dermatology 1990;23:870‐5. - PubMed
Whitehead 1991
    1. Whitehead A, Whitehead J. A general parametric approach to the meta‐analysis of randomized clinical trials. Statistics in Medicine 1991;10:1665‐77. - PubMed

Publication types

MeSH terms

LinkOut - more resources